MDA 19 (Synonyms: BZO-HEXOXIZID)

Name: MDA 19
Brand: MedChemExpress
SKU: HY-15451
Rating: 5.0 (2 reviews)

Cat. No.: HY-15451 Purity: 98.80%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

MDA 19 화학구조

CAS No. : 1048973-47-2

사이즈	재고	수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	해외재고보유	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	해외재고보유	Estimated Time of Arrival: December 31
Solid
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 2 publication(s) in Google Scholar

Other Forms of MDA 19:

MDA 19 (Standard) 견적 받기

2 Publications Citing Use of MCE MDA 19

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cannabinoid Receptor Isoform Specific Products:

View All Isoforms

CB1 CB2

Biological Activity
순도&문서
References
고객리뷰

제품 설명

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	63.4 1 Compound: 33, MDA19	Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]
CHO	EC₅₀	63.4 1 Compound: 33, MDA19	Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]
CHO	EC₅₀	867 1 Compound: 33, MDA19	Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]
CHO	EC₅₀	867 1 Compound: 33, MDA19	Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]
CHO	EC₅₀	63.4 1 Compound: 33, MDA19	Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]
CHO	EC₅₀	867 1 Compound: 33, MDA19	Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay	[PMID: 18666769]

In Vitro

MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 +/- 10.3 vs 162.4 +/- 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 +/- 2.1 vs 1130 +/- 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

분자량

349.43

화학식

C₂₁H₂₃N₃O₂

CAS No.

1048973-47-2

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(N/N=C1C(N(CCCCCC)C2=C\1C=CC=C2)=O)C3=CC=CC=C3

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

용액&용해도

In Vitro:

DMSO : 14.29 mg/mL (40.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8618 mL	14.3090 mL	28.6180 mL
5 mM	0.5724 mL	2.8618 mL	5.7236 mL
10 mM	0.2862 mL	1.4309 mL	2.8618 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.43 mg/mL (4.09 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.43 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.43 mg/mL (4.09 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

순도&문서

Purity: 98.80%

Select Batch:

Data Sheet (277 KB) SDS (254 KB)

COA (253 KB) LCMS (342 KB)

Handling Instructions (2659 KB)

References

[1]. Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry (2008), 51(16), 4932-4947. [Content Brief]

[2]. Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8618 mL	14.3090 mL	28.6180 mL	71.5451 mL
	5 mM	0.5724 mL	2.8618 mL	5.7236 mL	14.3090 mL
	10 mM	0.2862 mL	1.4309 mL	2.8618 mL	7.1545 mL
	15 mM	0.1908 mL	0.9539 mL	1.9079 mL	4.7697 mL
	20 mM	0.1431 mL	0.7155 mL	1.4309 mL	3.5773 mL
	25 mM	0.1145 mL	0.5724 mL	1.1447 mL	2.8618 mL
	30 mM	0.0954 mL	0.4770 mL	0.9539 mL	2.3848 mL
	40 mM	0.0715 mL	0.3577 mL	0.7155 mL	1.7886 mL

MDA 19 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MDA 191048973-47-2BZO-HEXOXIZIDMDA19MDA-19Cannabinoid ReceptorcannabinoidCB2antiallodynicneuropathicpainInhibitorinhibitorinhibit

최근 본 상품:

상품명

Requested Quantity *

고객명 *

호칭

메일주소 *

전화번호 *

Department

회사명 *

City

도

Country or Region *

비고

상품명

Lot #

고객명 *

메일주소 *

전화번호

Department *

회사명 *

Country or Region *

비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

MDA 19 (Synonyms: BZO-HEXOXIZID)

고객리뷰

Other Forms of MDA 19:

MDA 19 Related Antibodies

2 Publications Citing Use of MCE MDA 19

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cannabinoid Receptor Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

MDA 19 Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

MDA 19 Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report